Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Under the terms of the deal, ACELYRIN shareholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock. Once the deal closes, Alumis stockholders will own about ...

Alumis (Nasdaq: ALMS) and Acelyrin (Nasdaq: SLRN) have agreed to merge in an all-stock deal, creating a late-stage ...

Alumis (ALUM) stock dropped while Acelyrin (SLRN) stock gained in the premarket as the biopharma companies announced an all-stock merger deal. Read more here.

Alumis (ALMS) and Acelyrin (SLRN) announced a definitive merger agreement under which Alumis and Acelyrin will merge in an all-stock ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ACELYRIN, INC. (NASDAQ: SLRN) to Alumis ...

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on ACELYRIN, INC. (SLRN – Research Report). The company’s ...